$NVAX,,,Closed the day @ $2.14 and had a nice AH j
Post# of 22756
(Total Views: 243)
Posted On: 07/18/2017 12:06:08 AM
$NVAX,,,Closed the day @ $2.14 and had a nice AH jump of $.09 because of the news shown in the BioPharm Update on the previous post. I expect pps to keep rising tomorrow.
Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
PR Newswire PR NewswireJuly 17, 2017
- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
- Provide an Update on the RSV F Vaccine Development Program
GAITHERSBURG, Md., July 17, 2017 /PRNewswire/ -- Novavax, Inc. (NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults and well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.
Preliminary webcast agenda:
1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
3. Update on the Prepare™ trial for Infants via Maternal Immunization
Conference call details are as follows:
Date: Monday, July 24, 2017
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events"
Conference call and webcast replay:
Dates: Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET, July 31, 2017
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events", until October 24, 2017
About Novavax
Novavax, Inc. (NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
PR Newswire PR NewswireJuly 17, 2017
- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
- Provide an Update on the RSV F Vaccine Development Program
GAITHERSBURG, Md., July 17, 2017 /PRNewswire/ -- Novavax, Inc. (NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults and well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.
Preliminary webcast agenda:
1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
3. Update on the Prepare™ trial for Infants via Maternal Immunization
Conference call details are as follows:
Date: Monday, July 24, 2017
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events"
Conference call and webcast replay:
Dates: Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET, July 31, 2017
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 54820069
Webcast: www.novavax.com, "Investors"/ "Events", until October 24, 2017
About Novavax
Novavax, Inc. (NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼